Shots:
- Daiichi Sankyo & AZ have reported P-III (DESTINY-Lung04) trial data assessing Enhertu (5.4mg/kg) vs SoC (Pt-pemetrexed doublet CT + Keytruda) in 454 pts with unresectable, locally advanced or metastatic, nsq-NSCLC harboring a HER2 exon 19 or 20 mutation
- Trial showed that Enhertu improved PFS as 1L treatment, with trial continuing to evaluate 2EPs incl. OS; data to be presented at an upcoming medical meeting & shared with global regulatory authorities
- Enhertu is a HER2-directed ADC built on Daiichi’s DXd technology, comprising a HER2 mAb linked via cleavable tetrapeptide linkers to a topoisomerase I inhibitor payload, and is being jointly developed & commercialized by Daiichi Sankyo & AZ
Ref: Businesswire | Image: Daiichi Sankyo & AstraZeneca | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
